CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company specializes in developing treatments for brain cancers. Participants can join virtual one-on-one meetings with management and view a video webcast of the presentation starting March 9 at 7:00 AM ET. CNS's lead drug candidate, Berubicin, targets glioblastoma multiforme and has shown a 44% response rate in previous trials. A Phase 2 trial is expected in 2021.

HOUSTON, March 4, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. 

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website here.

The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the IR Calendar page of the Investors section of the Company's website (cnspharma.com) and will be archived for 90 days following the event.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial (with extensive PK) in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-global-life-sciences-conference-301240163.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

When will CNS Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?

CNS Pharmaceuticals will present at the conference on March 9-10, 2021.

What is the focus of CNS Pharmaceuticals' research?

CNS Pharmaceuticals focuses on developing treatments for primary and metastatic cancers of the brain and central nervous system.

What is Berubicin and its significance for CNSP?

Berubicin is CNS Pharmaceuticals' lead drug candidate for treating glioblastoma multiforme, showing a 44% disease control rate in prior Phase 1 trials.

How can investors attend the presentation by CNS Pharmaceuticals?

Investors can register for the H.C. Wainwright Global Life Sciences Conference to attend the virtual presentation and one-on-one meetings.

When will the video webcast of the CNS Pharmaceuticals presentation be available?

The video webcast will be available on-demand starting March 9, 2021, at 7:00 AM ET.

What clinical trials are planned for Berubicin in 2021?

CNS Pharmaceuticals plans to commence a Phase 2 clinical trial of Berubicin for glioblastoma multiforme in 2021.